文献速递妇科

法国罕见妇科肿瘤网络可改善颗粒细胞瘤手术质量

The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
PubMed 文献 · Gynecol Oncol · 2020-03-02

法国全国性研究纳入463例2011至2016年确诊的颗粒细胞瘤患者,分析手术与指南的符合度。结果显示完全符合仅14%,但网络实施后手术符合度随时间显著提高,提示国家级罕见肿瘤网络可改善日常手术管理。

要点

  • 完全符合指南的手术仅占14%,部分符合46%,不符合30%。
  • 生存分析未显示最优手术与不完整手术的总生存或PFS显著差异,但趋势 favoring 最优手术。

核心结论

  • 2011至2016年间颗粒细胞瘤手术对指南的符合度随时间提高,国家级罕见妇科肿瘤网络的实施似乎显著改善了手术管理。

研究设计与样本

  • 法国全国性研究,纳入463例(共识别639例)2011至2016年确诊为颗粒细胞瘤的患者,系统分析病历、手术和病理报告以评估手术与指南的符合度。

主要发现

  • 诊断中位年龄49岁(范围10-89),肿瘤中位大小94 mm(范围5-400)。
  • 240例(52%)行根治性手术,98例(21%)行保留生育功能手术,76例(16%)行手术分期,289例(62%)行子宫内膜评估。
  • 手术完全符合指南65例(14%),部分符合213例(46%),不符合137例(30%),不可评估48例(10%)。
  • 生存分析未证明总生存或无进展生存有显著差异,但最优手术相较于不完整/非最优手术有趋势性获益。

关键数值与推荐

  • 完全符合定义为根据FIGO分期行保守(单侧输卵管卵巢切除术)或根治性手术(子宫切除及双侧输卵管卵巢切除术)并包括手术分期(大网膜切除、腹膜活检和腹膜细胞学)。
  • 部分符合指行保守或根治性手术但未行手术分期;不符合定义为非指南推荐的最优手术。

临床怎么用

  • 在颗粒细胞瘤日常手术中应参照罕见妇科肿瘤网络指南,注重手术分期和子宫内膜评估以提高符合度。
  • 参与国家级罕见肿瘤网络及多学科肿瘤委员会可能促进手术管理规范化。

局限性

  • 生存分析未显示显著差异,仅观察到趋势,需更大样本或更长随访验证。
  • 10%病例手术符合度不可评估,可能影响结果完整性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The French national rare gynecological tumor network has been established to improve the quality of care through offering expertise in double reading histological diagnosis, reviewing cases and guiding management of these tumors through specialized multidisciplinary tumor boards and online clinical guidelines (www.ovaire-rare.com). The aim of this study is to evaluate the impact of the development and implementation of this network by assessing the conformity of medical practice with the guidelines concerning the granulosa cell tumors (GCTs). METHODS: This is a French nationwide study, including 463 patients (out of the 639 identified patients) with a definitive diagnosis of GCT between 2011 and 2016. Surgical practices were analyzed for conformity with the current guidelines (www.ovaire-rare.org). Medical records, surgical and pathological reports were systematically analyzed. Total conformity was defined by a conservative (unilateral salpingo-oophorectomy) or radical surgery (hysterectomy and bilateral salpingo-oophorectomy) including surgical staging (omentectomy, peritoneal biopsies and peritoneal cytology) according to the FIGO stage. Partial conformity referred to a conservative or radical surgery without surgical staging and non-conformity was defined as a non-optimal surgery as recommended by the guidelines. RESULTS: Median age at diagnosis was 49 years old (range 10-89). The median size of tumor was 94 mm (range 5-400). Radical surgery was performed in 240 patients (52%); while a fertility-sparing surgery was performed in 98 cases (21%). A surgical staging was performed in 76 cases (16%) and an evaluation of the endometrium in 289 cases (62%). Surgery was fully compliant with the guidelines in 65 patients (14%), partially compliant in 213 patients (46%), non-compliant in 137 patients (30%) and not assessable in 48 cases (10%). A statistically significant difference for compliance was observed in restaging surgery (p < 0,001), radical surgery (p = 0,017) and the period (before or after) of the implementation of the network (p < 0,001). Survival analyses did not allow us to demonstrate a significant difference in overall survival nor in PFS although there was a trend in favor of optimal surgery compared to incomplete/non optimal surgery. CONCLUSION: Surgical management's conformity to the guidelines increases over time from 2011 to 2016. According to this study, the implementation of a national network dedicated to rare gynecologic tumors seems to significantly improve the surgical management of the patients with ovarian granulosa cell tumors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lenck C, Chopin N, Gouy S, et al. The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study. Gynecol Oncol. 2020. PMID: 32131977. doi:10.1016/j.ygyno.2020.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。